We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bodisen | LSE:BODI | London | Ordinary Share | COM STK USD0.0001 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 6.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
TIDMBODI
RNS Number : 0530F
Bodisen Biotech Inc
15 April 2011
15 April 2011
BODISEN BIOTECH, INC.
Audited Results for the year ended 31 December 2010
Review and Extracts of the Form 10-K as required by the Securities and Exchange Commission
Consolidated Statements of Operations and other Comprehensive Income
For the years ended December 31, 2010 and 2009
Hot Features
Premium
Years ended
December 31
2009
2010 (as restated)
$ $
Net Revenue 6,595,178 5,217,277
Cost of Revenue 5,741,812 3,857,921
---------------- ----------------
Gross profit 853,366 1,359,356
Operating expenses
Selling expenses 439,184 151,756
General and administrative
expenses 4,558,294 2,060,553
Writedown of assets - 104,283
---------------- ----------------
Total operating expenses 4,997,478 2,316,592
---------------- ----------------
Loss from operations (4,144,112) (957,236)
Non-operating income (expense):
Other income (expense) (5,461) (2,178)
Interest income 72,216 3,275
Interest expense (92,956) (336)
Gain on sale of investment,
net - 842,145
Equity income in investment - 484,794
---------------- ----------------
Total non-operating income
(expense) (26,201) 1,327,700
---------------- ----------------
Income (loss) before provision
for income taxes (4,170,313) 370,464
Provision (benefit) for income
taxes - -
---------------- ----------------
Net income (loss) (4,170,313) 370,464
Other comprehensive income
Foreign currency translation
gain 1,146,420 10,745
Unrealised gain (loss) on
marketable equity security 605,577 2,021,600
---------------- ----------------
Comprehensive Income (loss) (2,418,316) 2,402,809
========= =========
Weighted average shares outstanding
:
Basic 18,825,318 18,710,520
========= =========
Diluted 18,825,318 18,710,520
========= =========
Earnings per share:
Basic (0.22) 0.02
========= =========
Diluted (0.22) 0.02
========= =========
Bodisen Biotech, Inc. and Subsidiaries
Consolidated Statement of Stockholders' Equity
For the years ended December 31, 2010 and 2009
Other Total
Additional
Common Stock Paid Comprehensive Statutory Accumulated Stockholders'
Shares Amount in Capital Income Reserve Deficit Equity
Balance,
December
31, 2008 as
restated 18,710,250 1,871 33,945,822 11,440,962 4,314,488 (8,250,183) 41,452,960
Change in
foreign
currency
translation
gain - - - 10,745 - - 10,745
Change in
unrealized
gain on
marketable
equity
security,
net of tax - - - 2,021,600 - - 2,021,600
Net income - - - - - 370,464 370,464
Transfer of
statutory
reserve - - - - - - -
----------- ----------- ----------- ----------- ----------- ----------- -----------
Balance,
December
31, 2009 as
restated 18,710,250 1,871 33,945,822 13,473,307 4,314,488 (7,879,719) 43,855,769
Common stock
issued for
services 2,800,000 280 1,399,720 - - - 1,400,000
Change in
foreign
currency
translation
gain - - - 1,146,420 - - 1,146,420
Change in
unrealized
gain on
marketable
equity
security,
net of tax - - - 605,577 - - 605,577
Net loss - - - - - (4,170,313) (4,170,313)
-
Transfer to
statutory
reserve - - - - - - -
----------- ----------- ----------- ----------- ----------- ----------- -----------
Balance,
December
31, 2010 21,510,250 2,151 35,345,542 15,225,304 4,314,488 (12,050,032) 42,837,453
====== ====== ====== ====== ====== ====== ======
Consolidated Balance Sheet
As of December 31, 2010 and 2009
31 December
31 December 2009
2010 (as restated)
$ $
ASSETS
CURRENT ASSETS:
Cash & cash equivalents 3,675,209 4,824,135
Accounts receivable and
other receivable, net of
allowance for doubtful
accounts of $1,005,992
and $2,196,072 4,499,673 2,346,583
Other receivables 9,185 26,298
Note receivable 1,517,000 -
Inventory 1,198,134 991,140
Advances to suppliers 665,765 541,754
Prepaid expense and other
current assets 8,598 966,942
--------------------- ---------------------
Total current
assets 11,573,564 9,696,852
PROPERTY AND EQUIPMENT, net 22,870,340 11,837,406
CONSTRUCTION IN PROGRESS - 10,422,641
MARKETABLE SECURITY,
AVAILABLE-FOR-SALE 8,780,867 8,175,290
INTANGIBLE ASSETS, net 4,813,409 4,873,904
--------------------- ---------------------
TOTAL ASSETS 48,038,180 45,006,093
=========== ===========
LIABILITIES AND STOCKHOLDERS'
EQUITY
CURRENT LIABILITIES:
Accounts payable 1,256,681 71,504
Accrued expenses 811,181 161,673
Deferred revenue 1,615,865 917,147
--------------------- ---------------------
Total current
liabilities 3,683,727 1,150,324
Long-term note payable 1,517,000 -
=========== ===========
TOTAL LIABILITIES: 5,200,727 1,150,324
=========== ===========
STOCKHOLDERS' EQUITY:
Preferred stock, $0.0001
per share; authorized
5,000,000 shares;
nil issued and
outstanding - -
Common stock, $0.0001 per
share; authorized
30,000,000 shares;
issued and outstanding
21,510,250 and
18,710,250 2,151 1,871
Additional paid-in
capital 35,345,542 33,945,822
Accumulated other
comprehensive income 15,225,304 13,473,307
Statutory reserve 4,314,488 4,314,488
Retained Earnings (12,050,032) (7,879,719)
--------------------- ---------------------
Total
stockholders'
equity 42,837,453 43,855,769
--------------------- ---------------------
TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY 48,038,180 45,006,093
=========== ===========
Consolidated Statements of Cash Flows
For the years ended December 31, 2010 and 2009
Years Ended December
31
2009
2010 (as restated)
$ $
CASH FLOWS FROM OPERATING
ACTIVITIES:
Net income (loss) (4,170,313) 370,464
Adjustments to reconcile
net income (loss) to net
cash provided by operating
activities:
Depreciation and
amortization 924,633 818,995
Common stock issued for
service 1,400,000 -
Gain on sale of investment,
net - (842,145)
Loss on disposal of fixed
asset - 104,283
Allowance (recovery) of bad
debts 1,221,393 (469,246)
Equity income in investment - (484,794)
(Increase) / decrease in
assets:
Accounts
receivable (3,803,357) 713,597
Other
receivables 17,563 312,616
Inventory (168,920) 2,016,028
Advances to
suppliers (102,930) (541,422)
Prepaid expense 966,730 (178,385)
Other assets - 14,634
Increase / (decrease) in
current liabilities:
Accounts payable 1,153,772 (638,890)
Accrued expenses 628,388 59,080
Deferred revenue 1,211,162 (1,175,304)
--------------------- ---------------------
Net cash provided by
operating activities (721,879) 79,511
--------------------- ---------------------
CASH FLOWS FROM INVESTING
ACTIVITIES
Acquisition of property and
equipment (558,916) (15,289)
Issuance of note receivable (1,479,400) -
Proceeds from sale of
investments - 4,667,216
--------------------- ---------------------
Net cash provided by (used
in) investing activities (2,038,316) 4,651,927
--------------------- ---------------------
CASH FLOWS FROM INVESTING
ACTIVITIES
Proceeds from issuance of
long-term note payable 1,479,400 -
--------------------- ---------------------
Net cash provided by
investing activities 1,479,400
--------------------- ---------------------
Effect of exchange rate
changes on cash and cash
equivalents 131,869 1,981
--------------------- ---------------------
NET INCREASE IN CASH & CASH
EQUIVALENTS (1,148,926) 4,733,419
CASH & CASH EQUIVALENTS,
BEGINNING OF PERIOD 4,824,135 90,716
--------------------- ---------------------
CASH & CASH EQUIVALENTS, END
OF PERIOD 3,675,209 4,824,135
=========== ===========
SUPPLEMENTAL DISCLOSURE OF
CASH FLOW INFORMATION:
Interest paid - -
=========== ===========
Income taxes paid - -
=========== ===========
SUPPLEMENTAL NON-CASH INVESTING
AND FINANCING ACTIVITIES:
Transfer of construction in
process to property and equipment 10,793,047 7,166,581
=========== ===========
EXTRACT FROM MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
FORWARD LOOKING STATEMENTS
The following information should be read in conjunction with the selected consolidated financial and operating data and the accompanying consolidated financial statements and related notes thereto included in the annual report. The following discussion may contain forward-looking statements that reflect the Company's plans, estimates and beliefs. The actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to these differences include, but are not limited to, those discussed below and elsewhere in the annual report, particularly in "Risk Factors" and "Note Regarding Forward Looking Statements."
Virtually all of the Company's revenues and expenses are denominated in Renminbi ("RMB"), the currency of the People's Republic of China. Because the Company reports its financial statements in U.S. dollars, we are exposed to translation risk resulting from fluctuations of exchange rates between the RMB and the U.S. dollar. There is no assurance that exchange rates between the RMB and the U.S. dollar will remain stable. A devaluation of the RMB relative to the U.S. dollar could adversely affect the business, financial condition and results of operations. See "Risk Factors." We do not engage in currency hedging and to date, inflation has not had a material impact on our business.
Unless otherwise specified, references to Notes to the consolidated financial statements are to the Notes to the audited consolidated financial statements as of December 31, 2010 and 2009 and for the two-year period ended December 31, 2010.
Overview
The Company is incorporated under the laws of the state of Delaware and the operating subsidiary, Yang Ling, is headquartered in ShaanxiProvince, the People's Republic of China. We are engaged in developing, manufacturing and selling organic fertilizers, liquid fertilizers, pesticides and insecticides in the People's Republic of China and produce numerous proprietary product lines, from pesticides to crop-specific fertilizers. We market and sell our products to distributors throughout the People's Republic of China, and these distributors, in turn, sell our products to farmers. We also conduct research and development to further improve existing products and develop new formulas and products.
Results of Operations
Year ended December 31, 2010 compared to year ended December 31, 2009
Revenue:
We generated revenue of $ 6.60 million for the year ended December 31, 2010, an increase of 1.38 million or 26.4%, compared to $5.22 million for the year ended December 31, 2009. The increase in revenue is primarily attributable to the domestic recovery as the financial crisis has past and the Chinese government's preferential policies for farmers. Chinese government gives farmers $70-$140 bonus per acre land to encourage them to plant. Because of the bonus the farmers get, they have the economic ability to purchase more of our products.
Gross Profit:
We achieved a gross profit of $853,366 for the year ended December 31, 2010, a decrease of $505,990 or 37.2%, compared to $1,359,356 for the year ended December 31, 2009. The gross profit percentage was 12.9% and 26.1% for the years ended December 31, 2010 and 2009, respectively. The decrease in gross profit margin was primarily attributable to higher cost of goods sold as a result of an increase in the sale of compound fertilizers during the fiscal year ended December 31, 2010.
Operating expenses:
We incurred operating expenses of $4,997,478 for the year ended December 31, 2010, a increase of $2,680,886 or 115.7%, compared to $2,316,592 for the year ended December 31, 2009. The increase in our operating expenses is primarily attributable to the issuance of 2,800,000 shares of common stock valued at $1,400,000 issued to key employees and consultants in December 2010, the increase in sales revenue and the domestic industry price increases.
Selling expenses accounted for $439,184 of our operating expenses for the year ended December 31, 2010, a increase of $287,428 or 189.4%, compared to $151,756 for the year ended December 31, 2009. The increase in our selling expenses is primarily attributable to increase the advertising fees paid.
General and administrative expenses accounted for $4,558,294 for the year ended December 31, 2010, an increase of $2,497,741 or 121.2% compared to $2,060,553 for the year ended December 31, 2009. The increase in general and administrative expenses is primarily related to the issuance of 2,800,000 shares of common stock valued at $1,400,000 issued to key employees and consultants in December 2010 and the $2,240,000 of bad debt incurred as a result of the floods during the summer of 2010.
Non Operating Income and Expenses:
We had total non-operating income of $26,201 for the year ended December 31, 2010, a decrease of $ 1,353,901 or 102.0%, compared to $1,327,700 for the year ended December 31, 2009. Total non-operating income includes interest income of $ 72,216 for the year ended December 31, 2010 compared to $3,275 for year
ended December 31, 2009 and includes interest expense of $ 92,956 for the year ended December 31, 2010 compared to $336 for year ended December 31, 2009. Also included in non-operating income (expense) for the year ended December 31 2010 is a gain of $842,145 related to a sale of investment and a gain of $484,728 related to equity income of an investment that we account for under the equity method. During the year ended December 31, 2010, we did not incur any gains related to the sale on investment or equity income in investment.
Net Income:
For the foregoing reasons, we had a net loss of $ 4,170,313 for the year ended December 31, 2010, a decrease in net income of $4,540,777 or (-1,225.7%), compared to a net income of $370,464 for the year ended December 31, 2009. We had earnings (loss) per share of ($0.22) and $0.02 for the year ended December 31, 2010 and 2009, respectively.
Liquidity and Capital Resources
We are primarily a parent holding company for the operations carried out by our indirect operating subsidiary, Yang Ling, which carries out its activities in the People's Republic of China. Because of our holding company structure, our ability to meet our cash requirements apart from our financing activities, including payment of dividends on our common stock, if any, substantially depends upon the receipt of dividends from our subsidiaries, particularly Yang Ling.
During 2008, we exchanged $3,291,264 of receivables for a 28.8% ownership interest in a Chinese company, Shanxi Jiali Pharmaceutical Co. Ltd ("Jiali"). We have written down the value of this investment by $987,860 at December 31, 2008. This investment is accounted for under the equity method and we recorded equity income in this investment for the year ended December 31, 2009 of $484,728. We received our ownership in Jiali a result of settling an old receivable. We believed that we had a better chance of realizing the value of this receivable by accepting ownership in Jiali than pursuing a cash payment from our customer. In September 2009 Jiali merged with a U.S. public company trading on the OTC Bulletin Board, which should give us liquidity in this
investment. At the date of the change, the investment was valued at $2,829,732. As of December 31, 2010, the fair value of the investment is $7.56 million which is reflected in the consolidated balance sheet at December 31, 2010. The unrealized gain of $605,577 is reflected as other comprehensive income in the consolidated statement of stockholder's equity. On March 19, 2010, we obtained a bank loan for 10,000,000 RMB (approximately $1,517,000). The loan has an 8.1% annual interest rate, matures on March 19, 2012 and is secured by our land use rights and production facility.
As of December 31, 2010, we had $3,675,209 of cash and cash equivalents compared to $4,824,135 as of December 31, 2009. Based on past performance and current expectations, we believe our cash and cash equivalents and cash generated from operations will satisfy our current working capital needs, capital expenditures and other liquidity requirements associated with our operations. However, to the extent our allowance for bad debts in insufficient to cover our actual bad debt experience, our liquidity would be negatively impacted.
Cash Flows
Operating:
Cash used in operations for the year ended December 31, 2010 was $721,879 compared to cash provided by operations of $79,511 for the year ended December 31, 2009. The decrease in the cash provided by operating activities is principally due to an increase in accounts receivable.
Investing:
Our investing activities used $2,038,316 of cash for the year ended December 31, 2010, compared to cash generated by investing activities of $4,667,216 for the year ended December 31, 2009. The decrease is primarily attributable to the sale of an investment in 2009 for $4,667,216.
Financing:
We had no cash provided by financing activities for the year ended December 31, 2009. We had $1,479,400 cash provided by financing activities for the year ended December 31, 2010.
Contractual Commitments
The following table is a summary of contractual cash obligations for the periods indicated that existed as of December 31, 2010, and is based on information appearing in the notes to Consolidated Financial Statements included elsewhere in this Annual Report on Form 10-K.
Payments due by Period
----------------------------------------------------
Less More
than One to Three than
One Three to Five Five
Year Years Years Years Total
$ $ $ $ $
-------- ---------- --------- ------- ----------
Long-Term note
payable - 1,517,000 - - 1,517,000
Operating leases 31,644 35,502 - - 67,146
Interest on debt
obligations 122,877 35,839 - - 158,716
-------- ---------- --------- ------- ----------
Total 154,521 1,588,341 - - 1,742,862
======== ========== ========= ======= ==========
Off-Balance Sheet Arrangements
We currently do not have any material off-balance sheet arrangements except for the remaining pre-payments under the land-lease arrangement described above.
Critical Accounting Policies and Estimates
Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expenses amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.
We believe the following is among the most critical accounting policies that impact our consolidated financial statements. We suggest that our significant accounting policies, as described in our condensed consolidated financial statements in the Summary of Significant Accounting Policies, be read in conjunction with this Management's Discussion and Analysis of Financial Condition and Results of Operations.
Accounts receivable
We maintain reserves for potential credit losses on accounts receivable and record them primarily on a specific identification basis. In order to establish reserves, we review the composition of accounts receivable and analyze historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. This analysis and evaluation requires the use of judgments and estimates.
Because of the nature of the evaluation, certain judgments and estimates are subject to change, which may require adjustments in future periods.
Inventories
We value inventories at the lower of cost (determined on a weighted average basis) or market. When evaluating our inventory, we compare the cost with the market value and make allowance to write them down to market value, if lower. The determination of market value requires the use of estimates and judgment by our management.
Intangible assets
We evaluate intangible assets for impairment, at least on an annual basis and whenever events or changes in circumstances indicate that the carrying value may not be recoverable from its estimated future cash flows. This evaluation requires the use of judgments and estimates, in particular with respect to recoverability.
Recoverability of intangible assets, other long-lived assets and, goodwill is measured by comparing their net book value to the related projected undiscounted cash flows from these assets, considering a number of factors including past operating results, budgets, economic projections, market trends and product development cycles. If the net book value of the asset exceeds the related undiscounted cash flows, the asset is considered impaired, and a second test is performed to measure the amount of impairment loss
Revenue Recognition
Our revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 104. Because collection is not reasonably assured, sales revenue is recognized using the cost recovery method. Under the cost recovery method, no profit is recognized until cash payments exceed the cost of the goods sold.
Recent Accounting Pronouncements
In January 2010, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2010-06, Improving Disclosures about Fair Value Measurements ("ASU No. 2010-06"). The new standard addresses, among other things, guidance regarding activity in Level 3 fair value measurements. Portions of ASU No. 2010-06 that relate to the Level 3 activity disclosures are effective for the annual reporting period beginning after December 15, 2010. The Company will provide the required disclosures beginning with the Company's Annual Report on Form 10-K for the year ending December 31, 2011. Based on the initial evaluation, we do not anticipate a material impact to our financial position, results of operations or cash flows as a result of this change.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Note 1 - Organization and Basis of Presentation
Organization and Line of Business
The accompanying consolidated financial statements include the accounts of Bodisen Biotech, Inc., its 100% wholly-owned subsidiaries Bodisen Holdings, Inc.
(BHI), Yang Ling Bodisen Agricultural Technology Co., Ltd ("Agricultural"), which was incorporated in March 2005, and Sinkiang Bodisen Agriculture Material Co., Ltd. ("Material"), which was incorporated in June 2006, as well as the accounts of Agricultural's 100% wholly- owned subsidiary Yang Ling Bodisen Biology Science and Technology Development Company Limited ("BBST"). The Company is engaged in developing, manufacturing and selling organic fertilizers, liquid fertilizers, pesticides and insecticides in the People's Republic of China and produces numerous proprietary product lines, from pesticides to crop-specific fertilizers. The Company markets and sells its products to distributors throughout the People's Republic of China, and these distributors, in turn, sell the products to farmers.
Note 2 - Summary of Significant Accounting Policies
Basis of Presentation
The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America. All significant intercompany transactions and balances have been eliminated. The Company's functional currency is the Chinese Yuan Renminbi ("RMB"); however the accompanying consolidated financial statements have been translated and presented in United States Dollars ($ or "USD").
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions.
These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. It is possible that accounting estimates and assumptions may be material to the Company due to the levels of subjectivity and judgment involved.
Cash and Cash Equivalents
Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less.
Accounts Receivable
The Company maintains reserves for potential credit losses for accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. Reserves are recorded based on the Company's historical collection history.
Advances to Suppliers
The Company advances to certain vendors for purchase of its material. The advances to suppliers are interest free and unsecured.
Inventories
Inventories are valued at the lower of cost (determined on a weighted average basis) or market. The Management compares the cost of inventories with the market value and allowance is made for writing down their inventories to market value, if lower.
Property & Equipment and Construction In Progress
Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the straight-line method for substantially all assets with estimated lives of:
Operating equipment 10 years Vehicles 8 years Office equipment 5 years Buildings 30 years
The following are the details of the property and equipment at December 31, 2010 and 2009, respectively:
December December
31, 31,
2010 2009
------------ ------------
Operating equipment $ 10,181,140 $ 4,650,919
Vehicles 617,703 687,791
Office equipment 98,420 87,552
Buildings 15,016,045 8,656,077
------------ ------------
25,913,308 14,082,339
Less accumulated depreciation (3,042,968) (2,244,933)
Property and equipment,
net $ 22,870,340 $ 11,837,406
============ ============
Depreciation expense for the years ended December 31, 2010 and 2009 was $703,637 and $559,960, respectively.
On December 31, 2009, the Company had Construction in Progress representing the construction of the Company's manufacturing plant amounting to $10,422,641. During the year ended December 31, 2010, there was $10,793,047 transferred from construction in progress to property and equipment.
Marketable Securities
The Company applies the guidance of ASC Topic 320 "Investments-Debt and Equity Securities," which requires investments in equity securities to be classified as either trading securities or available-for-sale securities. Marketable securities that are bought and held principally for the purpose of selling them in the near term are classified as trading securities and are reported at fair value, with unrealized gains and losses recognized in earnings. Marketable equity securities not classified as trading are classified as available for sale, and are carried at fair market value, with the unrealized gains and losses, net of tax, included in the determination of comprehensive income and reported in shareholders' equity.
Long-Lived Assets
The Company applies the provisions of ASC Topic 360, "Property, Plant, and Equipment," which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review, the Company believes that as of December 31, 2010 and 2009, there was no significant impairment of its long-lived assets.
Intangible Assets
Intangible assets consist of Rights to use land and Fertilizers proprietary technology rights. The Company follows ASC Topic 350 in accounting for intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets' carrying amounts. There were no impairment losses recorded on intangible assets for the years ended December 31, 2010 and 2009
Fair Value of Financial Instruments
For certain of the Company's financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their fair values due to their short maturities. In addition, the Company has long-term debt with financial institutions. The carrying amounts of the line of credit and other long-term liabilities approximate their fair values based on current rates of interest for instruments with similar characteristics.
Fair Value Measurements
ASC Topic 820, "Fair Value Measurements and Disclosures," requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, "Financial Instruments," defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels of valuation hierarchy are defined as follows:
-- Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.
-- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
-- Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement.
The Company analyzes all financial instruments with features of both liabilities and equity under ASC 480, "Distinguishing Liabilities from Equity," and ASC 815.
The following table represents our assets and liabilities by level measured at fair value on a recurring basis as of December 31, 2010.
Description Level Level 2 Level 3
1
Assets
Marketable securities $ 8,780,867 $ - $ -
The Company did not identify any other non-recurring assets and liabilities that are required to be presented in the consolidated balance sheets at fair value in accordance with ASC 825.
Revenue Recognition
The Company's revenue recognition policies are in compliance with Staff accounting bulletin (SAB) 104. Because collection is not reasonably assured, sales revenue is recognized using the cost recovery method. Under the cost recovery method, no profit is recognized until cash payments exceed the cost of the goods sold.
Advertising Costs
The Company expenses the cost of advertising as incurred or, as appropriate, the first time the advertising takes place. Advertising costs for the years ended December 31, 2010 and 2009 were insignificant.
Stock-Based Compensation
The Company records stock-based compensation in accordance with ASC Topic 718, "Compensation - Stock Compensation." ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee's requisite service period. The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees. There were 426,000 options outstanding as of December 31, 2010.
Income Taxes
The Company accounts for income taxes in accordance with ASC Topic 740, "Income Taxes." ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Under ASC 740, a tax position is recognized as a benefit only if it is "more likely than not" that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the "more likely than not" test, no tax benefit is recorded. The adoption had no effect on the Company's consolidated financial statements.
Foreign Currency Translation
The accounts of the Company's Chinese subsidiaries are maintained in the RMB and the accounts of the U.S. parent company are maintained in the USD. The accounts of the Chinese subsidiaries are were translated into USD in accordance with Accounting Standards Codification ("ASC") Topic 830 "Foreign Currency Matters," with the RMB as the functional currency for the Chinese subsidiaries. According to Topic 830, all assets and liabilities were translated at the exchange rate on the balance sheet date; stockholders' equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, "Comprehensive Income." Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the statement of operations.
Foreign Currency Transactions and Comprehensive Income
Accounting principles generally require that recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company's Chinese subsidiaries is the Chinese Yuan Renminbi. Translation gains of $9,274,169 and $8,127,749 at December 31, 2010 and 2009, respectively are classified as an item of other comprehensive income in the stockholders' equity section of the consolidated balance sheet. During the year ended December 31, 2010 and 2009 other comprehensive income in the consolidated statements of operations and other comprehensive income included translation gains (loss) of $1,146,420 and $10,745, respectively. A detail of accumulated other comprehensive income is summarized below:
Total Other
Foreign Unrealized Comprehensive
Currency Gain (loss) Income
$ $ $
---------- ------------- ---------------
Balance, December
31, 2008 8,117,004 3,323,958 11,440,962
Adjustments 10,745 2,021,600 2,032,345
---------- ------------- ---------------
Balance, December
31, 2009 8,127,749 5,345,558 13,473,307
Adjustments 1,146,420 605,577 1,751,997
---------- ------------- ---------------
Balance, December
31, 2010 9,274,169 5,951,135 15,225,304
========== ============= ===============
Basic and Diluted Earnings Per Share
Earnings per share is calculated in accordance with the ASC Topic 260, "Earnings Per Share." Basic earnings per share is based upon the weighted average number of common shares outstanding. Diluted earnings per share is based on the assumption that all dilutive convertible shares and stock warrants were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. There were 426,000 and 426,000 options as of December 31, 2010 and 2009 that were excluded from the diluted loss per share calculation due to their exercise price being greater than the Company's average stock price for the year.
Statement of Cash Flows
In accordance with ASC Topic 230, "Statement of Cash Flows," cash flows from the Company's operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets.
Segment Reporting
ASC Topic 280, "Segment Report," requires use of the "management approach" model for segment reporting. The management approach model is based on the way a company's management organizes segments within the company for making operating decisions and assessing performance. ASC Topic 280 has no effect on the Company's consolidated financial statements as the Company consists of one reportable business segment. All revenue is from customers in People's Republic of China and all of the Company's assets are located in People's Republic of China.
Reclassifications
Certain amounts in the 2009 consolidated financial statements have been reclassified to conform with the 2010 presentation with no effect to previously reported net income (loss).
Recent Accounting Pronouncements
In August 2009, the FASB issued Accounting Standards Update 2009-05, Fair Value Measurements and Disclosures (ASC 820) Measuring Liabilities at Fair Value. This guidance clarifies that in circumstances in which a quoted price in an active market for an identical liability is not available, a reporting entity is required to measure fair value of such liability using one or more of the of the techniques prescribed by the update. This guidance is effective for the first reporting period beginning after issuance, which is the period ending December 31, 2009. The impact of the adoption of this guidance was not significant to our consolidated financial statements.
In January 2010, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2010-06, Improving Disclosures about Fair Value Measurements ("ASU No. 2010-06"). The new standard addresses, among other things, guidance regarding activity in Level 3 fair value measurements. Portions of ASU No. 2010-06 that relate to the Level 3 activity disclosures are effective for the annual reporting period beginning after December 15, 2010. The Company will provide the required disclosures beginning with the Company's Annual Report on Form 10-K for the year ending December 31, 2011. Based on the initial evaluation, we do not anticipate a material impact to our financial position, results of operations or cash flows as a result of this change.
On March 5, 2010, the FASB issued ASU No. 2010-11 Derivatives and Hedging Topic 815 "Scope Exception Related to Embedded Credit Derivatives." This ASU clarifies the guidance within the derivative literature that exempts certain credit related features from analysis as potential embedded derivatives requiring separate accounting. The ASU specifies that an embedded credit derivative feature related to the transfer of credit risk that is only in the form of subordination of one financial instrument to another is not subject to bifurcation from a host contract under ASC 815-15-25, "Derivatives and Hedging - Embedded Derivatives - Recognition." All other embedded credit derivative features should be analyzed to determine whether their economic characteristics and risks are "clearly and closely related" to the economic characteristics and risks of the host contract and whether bifurcation is required. The ASU became effective for the Company on July 1, 2010. The adoption of this ASU did not have an impact on our consolidated financial statements.
In July 2010, the FASB issued ASU 2010-20, Disclosures about the Credit Quality of Financing Receivables and the Allowance for Credit Losses. This update amends codification Topic 310 on receivables to improve the disclosures that an entity provides about the credit quality of its financing receivables and the related allowance for credit losses. As a result of these amendments, an entity is required to disaggregate by portfolio segment or class certain existing disclosures and provide certain new disclosures about its financing receivables and related allowance for credit losses. This guidance is being phased in, with the new disclosure requirements for period end balances effective as of December 31, 2010, and the new disclosure requirements for activity during the reporting period are effective March 31, 2011. The troubled debt restructuring disclosures in this ASU have been delayed by ASU 2011-01 Deferral of the Effective Date of Disclosures about Troubled Debt Restructurings in Update No. 2010-20, which was issued in January 2011.
Note 3 - Note Receivable
The note receivable is unsecured; bears interest at 9.1% per annum and originally due on March 25, 2011, but extended to September 25, 2011.
Note 4 - Inventory
Inventory at December 31, 2010 and 2009 consisted of the following:
December December
31, 31,
2010 2009
---------- ---------
Raw materials $ 563,088 $ 355,714
Packaging 45,288 59,729
Finished goods 589,758 575,697
---------- ---------
Inventory, net $ 1,198,134 $ 991,140
========== =========
Note 5 - Marketable Security
During 2008, the Company exchanged $3,291,264 of receivables for a 28.8% ownership interest in a Chinese company, Shanxi Jiali Pharmaceutical Co. Ltd ("Jiali"). The Company had written down the value of this investment by $987,860 at December 31, 2008. This investment was originally accounted for under the equity method and the Company recorded equity income in this investment through September 30, 2009. During the fourth quarter of 2009, Jiali was purchased by China Pediatric Pharmaceuticals, Inc. ("China Pediatric"), a public company. After the transaction, the Company owned 18.8% (or 2,018,590 shares) of China Pediatric. The Company then changed the accounting method for the investment from the equity method to the fair value method. At the date of the change, the investment was valued at $2,829,732. As of December 31, 2010 and 2009, the fair value of the investment is $8,780,867 and $8,175,290, respectively, which is reflected in the consolidated balance sheet. The Company recognized an unrealized gain of $605,577 and $2,021,600 for the year ended December 31, 2010 and 2009, respectively, which is reflected as accumulated other comprehensive income in the consolidated statement of stockholder's equity.
Note 6 - Intangible Assets
Net intangible assets at December 31, 2010 and 2009 were as follows:
December December
31, 31,
2010 2009
------------ ------------
Rights to use land $ 5,174,682 $ 4,999,724
Fertilizers proprietary technology
rights 1,213,600 1,173,600
------------ ------------
6,388,282 6,173,324
Less accumulated amortization (1,574,873) (1,299,421)
Intangibles, net $ 4,813,409 $ 4,873,903
============ ============
The Company's office and manufacturing site is located in Yang Ling Agricultural High-Tech Industries Demonstration Zone in the province of Shaanxi, People's Republic of China. The Company leases land per a real estate contract with the government of People's Republic of China for a period from November 2001 through November 2051. Per the People's Republic of China's governmental regulations, the Government owns all land.
During July 2003, the Company leased another parcel of land per a real estate contract with the government of the People's Republic of China for a period from July 2003 through June 2053.
The Company has recognized the amounts paid for the acquisition of rights to use land as intangible asset and amortizing over a period of fifty years.
The Company acquired Fluid and Compound Fertilizers proprietary technology rights on January 1, 2001 with a life ending December 31, 2011. The Company is amortizing Fertilizers proprietary technology rights over a period of ten years.
On July 15, 2008, the Company entered into a 50 year land rights agreement.
Amortization expense for the Company's intangible assets amounted to $220,996 and $219,035 for the years ended December 31, 2010 and 2009, respectively. Amortization of intangible assets for the years ended December 31, 2011, 2012, 2013, 2014 and 2015 is expected to be approximately $160,000, $101,000, $101,000, $101,000, and $101,000, respectively.
Note 7 - Long-Term Note Payable
On March 19, 2010, the Company obtained a bank loan for 10,000,000 RMB (approximately $1,517,000). The loan has an 8.1% annual interest rate, matures on March 19, 2012 and is secured by the Company's land use rights and facility.
Note 8 - Stockholders Equity
Common stock
On December 16, 2010, the Company issued 2,800,000 shares of common stock to certain officers, key employees and consultants for services rendered. The Company recorded the value of the common stock issued based on the closing market price of the Company's stock on the date of issuance as stock based compensation of $1,400,000.
Stock Options
Following is a summary of the stock option activity:
Weighted
Average Aggregate
Exercise
Options Price Intrinsic
Outstanding Price Value
------------ --------- ----------
Outstanding at December
31, 2008 536,000 $ 1.89 $
Granted -
Cancelled (110,000) 5.07
Exercised -
------------
Outstanding at December
31, 2009 426,000 1.07
Granted -
Cancelled -
Exercised -
Outstanding at December
31, 2010 426,000 1.07 -
============
Exercisable at December
31, 2010 426,000 $ 1.07 $ -
============
Following is a summary of the status of options outstanding at December 31, 2010:
Options Outstanding
-------------------------------------
Weighted
Average
Number Remaining
Range Contractual
of Outstanding Life
Exercise December
Price 31, 2010 (Years)
--------- ------------ ------------
$0.70 400,000.00 1.00
$6.72 26,000.00 0.26
426,000.00
============
Options Exercisable
-------------------------------------
Weighted
Average
Number Remaining
Range Contractual
of Outstanding Life
Exercise December
Price 31, 2010 (Years)
--------- ------------ ------------
$0.70 400,000.00 1.00
$6.72 26,000.00 0.26
426,000.00
============
Note 9 - Statutory Common Welfare Fund
As stipulated by the Company Law of the People's Republic of China (PRC), net income after taxation can only be distributed as dividends after appropriation has been made for the following:
i. Making up cumulative prior years' losses, if any;
ii. Allocations to the "Statutory surplus reserve" of at least 10% of income after tax, as determined under PRC accounting rules and regulations, until the fund amounts to 50% of the Company's registered capital;
iii. Allocations of 5-10% of income after tax, as determined under PRC accounting rules and regulations, to the Company's "Statutory common welfare fund", which is established for the purpose of providing employee facilities and other collective benefits to the Company's employees; and
iv. Allocations to the discretionary surplus reserve, if approved in the stockholders' general meeting.
Pursuant to the new Corporate Law effective on January 1, 2006, there is now only one "Statutory surplus reserve" requirement. The reserve is 10 percent of income after tax, not to exceed 50 percent of registered capital.
The Company did not appropriate a reserve for the statutory surplus reserve and welfare fund for the years ended December 31, 2010 and 2009.
Note 10 - Factory Location and Lease Commitments
The Company's principal executive offices are located at North Part of Xinquia Road, Yang Ling Agricultural High-Tech Industries Demonstration Zone Yang Ling, Shaanxi province, People's Republic of China. BBST owns two factories, which includes three production lines, an office building, one warehouse, and two research labs and, is located on 10,900 square meters of land. These leases require monthly rental payments of $2,637 and the leases expire in 2013.
Year Amount ----- ------- 2011 $ 31,644 2012 $ 31,644 2013 $ 3,858
Note 11 - Current Vulnerability Due to Certain Concentrations
Two vendors provided 24% and 15% of the Company's raw materials for the year ended December 31, 2010 and three vendors provided 30%, 23% and 20% of the Company's raw materials for the year ended December 31, 2009.
Two customers accounted for 12% and 9% of the Company's sales for the year ended December 31, 2010. Two customers accounted for 24% and 12% of the Company's sales for the year ended December 31, 2009.
The Company's operations are carried out in the PRC. Accordingly, the Company's business, financial condition and results of operations may be influenced by the political, economic and legal environments in the PRC, by the general state of the PRC's economy. The Company's business may be influenced by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things.
Note 12 - Income Taxes
At December 31, 2010, the Company has available for US and China income tax purposes a net operating loss carry forward of approximately $5,500,000 and $4,300,000, respectively that begin to expire in 2019 and 2022, respectively. These net operating loss carry forwards may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits.
At December 31, 2010 and 2009, the significant components of the deferred tax assets (liabilities) are summarized below:
December December
31, 31,
2010 2009
------------ ------------
Deferred tax assets:
Net operating loss - United
States $ 1,880,000 $ 1,295,000
Net operating loss - China 1,078,000 29,000
Allowance for doubtful accounts 251,000 688,000
Total deferred tax assets 3,209,000 2,012,000
Deferred tax liability:
Unrealised investment gain (1,488,000) (1,336,000)
Total deferred liability (1,488,000) (1,336,000)
------------ ------------
Net deferred tax asset 1,721,000 676,000
Less valuation allowance $ (1,721,000) $ (676,000)
$ - $ -
============ ============
The reconciliation of the effective income tax rate to the federal statutory rate for the years ended December 31, 2010 and 2009 is as follows:
December December
31, 31,
2010 2009
--------- ---------
Federal income tax rate 34.0% 34.0%
Foreign tax rate difference (9.0%) (9.0%)
Use of prior year NOLs 0.0% (25.0%)
Increase in valuation allowance (25.0%) 0.0%
--------- ---------
Effective income tax rate 0.0% 0.0%
========= =========
Note 13 - Litigation
From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is, however, subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Other than the matters described below, we are currently not aware of any such legal proceedings or claims that we believe would or could have, individually or in the aggregate, a material adverse affect on our business, financial condition, results of operations or liquidity.
Note 14 - Restatement
The Company changed its revenue recognition policy to the cost recovery method as the Company does not believe that collection is reasonably assured. Under the cost recovery method, no profit is recognized until cash payments exceed the cost of the goods sold and the Company records deferred revenue which is the gross profit that has not been realized. The following adjustments were made to the December 31, 2009 financial statements.
December
31, 2009 December
as Reported Adjustment 31, Restated
------------- ----------- --------------
Accounts
receivable $ 1,791,042 $ 555,541 $ 2,346,583
Current assets 9,141,311 555,541 9,696,852
Total assets 44,450,552 555,541 45,006,093
Deferred revenue - 917,147 917,417
Total current
liabilities 233,177 917,147 1,150,324
Retained earnings (7,518,113) (361,606) (7,879,719)
Total shareholders'
equity 44,217,375 (361,606) 43,855,769
Total
liabilities and
stockholders $ 44,450,552 $ 555,541 $ 45,006,093
For the For the
Year Ended Year Ended
December December
31, 2009 31, 2009
As Reported Adjustment As Restated
------------- ----------- -------------
Net revenue $ 4,351,164 $ 866,113 $ 5,217,277
Gross profit 493,243 866,113 1,359,356
General and
administrative
expenses 1,054,615 1,005,938 2,060,553
Total operating
expenses 1,310,654 1,005,938 2,316,592
Income (loss) from
operations (817,411) (139,825) (957,236)
Income (loss) before
provision for income
taxes 510,289 (139,825) 370,464
Net income (loss) 510,289 (139,825) 370,464
Comprehensive loss 2,542,634 (139,825) 2,402,809
Basic earnings (loss)
per share 0.03 (0.01) 0.02
Diluted earnings
(loss) per share $ 0.03 $ (0.01) $ 0.02
Note 15 - Subsequent Events
Pursuant to Financial Accounting Standards Board Accounting Standards Codification 855-10, the Company has evaluated all events or transactions that occurred from January 1, 2010, through the filing with the SEC. The Company did not have any material recognizable subsequent events during this period.
Our website is located at http://www.bodisen.com.
A copy of our annual report on Form 10-K is available at: http://www.sec.gov/Archives/edgar/data/1178552/000114420411022270/000114 4204-11-022270-index.htm
Copies may also be obtained by contacting the Investor Relations Department at our corporate offices by sending an e-mail message to info@bodisen.com.
Enquiries:
Charles Stanley Securities
(Nominated Adviser)
Russell Cook / Carl Holmes 020 7149 6000
This information is provided by RNS
The company news service from the London Stock Exchange
END
FR DKPDBABKDKQD
1 Year Bodisen Biotech Chart |
1 Month Bodisen Biotech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
